Buy Hikal Ltd For Target Rs.640 - ICICI Direct
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Strong Q2 driven by crop protection, pharma flat…
About the stock: Hikal is predominantly a B2B player that provides intermediates and active ingredients to global pharmaceutical, animal health, crop protection and specialty chemical companies.
* Pharma and crop protection are 62% and 38% of operating revenues, respectively. The pharma business is currently divided in 50:50 ratio of APIs and CDMO. Animal health business accounts for 20-25% of CDMO business
* In crop protection, 69% revenues are derived from CDMO while remaining is from proprietary products, specialty chemicals & specialty biocides
* One of the largest suppliers of Gabapentin API (CNS) and in crop protection, one of the largest suppliers of Thiabendazole (TBZ)
Q2FY22 Results: Hikal reported robust Q2FY22 results.
* Sales were up 26.1% YoY to | 469.1 crore
* EBITDA in Q2FY22 was at | 90.9 crore, up 30% YoY with margins at 19.4%
* Consequent adjusted PAT was at | 44.1 crore (up 63.5% YoY)
What should investors do? Hikal’s share price has grown by ~4.5x over the past five years (from ~| 123 in July 2016 to ~| 550 levels in Oct 2021).
* We change our view from HOLD to BUY on account of persistent guidance and visibility capex, which, in turn, can maintain the growth tempo
Target Price and Valuation: We value Hikal at | 640 i.e. 30x P/E on FY23E EPS
Key triggers for future price performance:
* Hikal continues to expand in both pharma, crop protection segments with separate focus and a calibrated approach
* Margin improvement on back of several cost rationalisation & efficiency improvement measures undertaken during the pandemic
* The crop protection segment maintaining growth due to sustained product offerings and optimum capacity utilisation
* Received manufacturing license for the production of APIs at Panoli site, to resume post validations over the next two quarters
* Raw material challenges expected to continue in the next few months.
Alternate Stock Idea: Apart from Hikal, in our healthcare coverage we like Laurus.
* Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis and biotechnology
* BUY with target price of | 785
To Read Complete Report & Disclaimer Click Here
https://secure.icicidirect.com/Content/StaticData/Disclaimer.html
Above views are of the author and not of the website kindly read disclaimer
.jpg)
